CAJ | 학술논문

背景:多发性骨髓瘤中存在一小部分比例的骨髓瘤干细胞,具有干细胞特性,有自我更新、无限增殖及多向分化的能力,是多发性骨髓瘤形成、进展、复发和耐药的根源.目的:就多发性骨髓瘤干细胞生物学特性、免疫表型、分离与鉴定及针对该类细胞的信号传导通路和靶向治疗进行综述.方法:应用计算机检索Medline数据库(1999-01/2009-04),以mutiple myeloma stem cells,heterogeneity,phenotypic analysis,signaling pathways,target therapy为检索词;应用计算机检索CNKI数据库(1999-01/2009-04)、CBM数据库(1999-01/2009-04),以多发性骨髓瘤干细胞、异质性、干细胞分离与鉴定、信号传导、靶向治疗为检索词.结果与结论:共收集126篇关于多发性骨髓瘤干细胞相关的文献,中文30篇,英文96篇,排除发表较早、重复及类似研究,纳入30篇符合标准的文献.目前普遍认为多发性骨髓瘤干细胞可能源于正常干细胞的积累突变和通过基因突变重新获得自我更新能力的祖细胞或已经完全分化的成熟细胞.循环克隆记忆性B细胞具有自我更新和多向分化的潜能,代表了多发性骨髓瘤干细胞.多发性骨髓瘤干细胞特异标志物正处于研究阶段,目前主要采用SP细胞分选和醛脱氢酶活性检测分离骨髓瘤干细胞.多发性骨髓瘤干细胞通过hedgehog,wnt及notch等信号通路而具有自我更新的特性,当这些信号传导通路出现异常时,就导致了肿瘤的发生及肿瘤细胞的无控制性增长.针对肿瘤干细胞进行选择性靶向治疗是制定肿瘤治疗策略的一个新的重要方向,肿瘤干细胞特有的表面标记和信号传导通路可以作为杀伤肿瘤干细胞而控制肿瘤发展的靶点.
배경:다발성골수류중존재일소부분비례적골수류간세포,구유간세포특성,유자아경신、무한증식급다향분화적능력,시다발성골수류형성、진전、복발화내약적근원.목적:취다발성골수류간세포생물학특성、면역표형、분리여감정급침대해류세포적신호전도통로화파향치료진행종술.방법:응용계산궤검색Medline수거고(1999-01/2009-04),이mutiple myeloma stem cells,heterogeneity,phenotypic analysis,signaling pathways,target therapy위검색사;응용계산궤검색CNKI수거고(1999-01/2009-04)、CBM수거고(1999-01/2009-04),이다발성골수류간세포、이질성、간세포분리여감정、신호전도、파향치료위검색사.결과여결론:공수집126편관우다발성골수류간세포상관적문헌,중문30편,영문96편,배제발표교조、중복급유사연구,납입30편부합표준적문헌.목전보편인위다발성골수류간세포가능원우정상간세포적적루돌변화통과기인돌변중신획득자아경신능력적조세포혹이경완전분화적성숙세포.순배극륭기억성B세포구유자아경신화다향분화적잠능,대표료다발성골수류간세포.다발성골수류간세포특이표지물정처우연구계단,목전주요채용SP세포분선화철탈경매활성검측분리골수류간세포.다발성골수류간세포통과hedgehog,wnt급notch등신호통로이구유자아경신적특성,당저사신호전도통로출현이상시,취도치료종류적발생급종류세포적무공제성증장.침대종류간세포진행선택성파향치료시제정종류치료책략적일개신적중요방향,종류간세포특유적표면표기화신호전도통로가이작위살상종류간세포이공제종류발전적파점.
BACKGROUND: Cancer stem cell is a minority population of cancer cells in multiple myeloma possessing the properties of stem cells: self-renewal, multi-directional differentiation and long-term proliferation, which mediating disease initiation, relapse, progression and drug resistance.OBJECTIVE: To review characteristics of biology, phenotypic analyses, sorting and identification in clonogenic myeloma cells, the signaling pathways with in myeloma stem cells and the target therapy related.METHODS: Application of computer search Medline database (1999-01/2009-04), using "multiple myeloma stem cells, heterogeneity, phenotypic analysis, signaling pathways, target therapy" as key words; application of computer search CNKI database (1999-01/2009-04) and CBM Database (1999-01/2009-04) using "multiple myeloma stem cells, heterogeneity, stem cell separation and identification, signal transduction, targeted therapy as key words".RESULTS AND CONCLUSION: We collected for 126 literatures on the multiple myeloma stem cell-related, which include 30 Chinese articles and 96 English articles, excluding published earlier, repeated, and similar studies into 30 sub-standard literatures. Now widely recognized that multiple myeloma stem cells may be derived from normal stem cells, the accumulation of mutations and by gene mutation in regaining self-renewal capacity of progenitor cells or fully differentiated mature cells. Circulating clonotypic memory B-cell populations have self-renewal and multi-directional differentiation potential, which represent the cancer stem cells in multiple myeloma. The exact phenotype of multiple myeloma cancer stem cells has not been definitively established and researched remains. At present, both the side population cells and aldehyde dehydrogenase (ALDH) activity assays were mainly capable of isolating multiple myeloma cancer stem cells. Which to possess self-renewal ability by Hedgehog ,Wnt and Notch signaling pathways. When these signal transduction pathways appear abnormal, leading to the occurrence of the tumor and tumor cell growth in non-controlled. Against the cancer stem cell targeted therapy is a new and important direction of selective therapeutic strategies. Cancer stem cell specific surface markers and signal transduction pathways can be used as anti-cancer stem cells to control tumor development targets.